Prevention Of Recurrence Of Atrial Fibrillation

GlaxoSmithKline520 enrolled

Overview

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

520

Conditions

Fibrillation, Atrial

Interventions

SB-207266DRUG

White, oval, biconvex tablets containing either 10mg, 25mg or 40mg

PlaceboOTHER

Placebo to match SB-207266

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Symptomatic persistent atrial fibrillation requiring DC cardioversion. * Duration of AF \>48 hrs. \<6 months Exclusion Criteria: * Concomitant Class I and/or III anti-arrhythmic drugs. * Amiodarone treatment within 3 months of the study. * Other inclusion or exclusion criteria to be determined by the physician and study sponsor.

Outcomes

Primary Outcomes

Time-to-first symptomatic AF (atrial fibrillation)

Time frame: Up to 26 Weeks

Secondary Outcomes

Time to first symptomatic or detected asymptomatic AF; spontaneous reversion to sinus rhythm prior to cardioversion

Time frame: Up to 26 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.